- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vaccinex Inc (VCNX)
Vaccinex Inc stock price live, this page displays OTC VCNX stock exchange data. View the VCNX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vaccinex Inc real time stock price chart below.
What Is the Vaccinex Inc Stock Price Today?
The Vaccinex Inc stock price today is 1.000.
What Is the Stock Symbol for Vaccinex Inc?
The stock symbol for Vaccinex Inc is "VCNX."
What Stock Exchange Does Vaccinex Inc Trade On?
Vaccinex Inc is listed and trades on the OTC Markets stock exchange.
Is Vaccinex Inc a Good Stock to Buy?
Determining whether Vaccinex Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VCNX quote. (ISIN: US9186403013)
What Is the Vaccinex Inc Stock Price Today?
The Vaccinex Inc stock price today is 1.000.
What Is the Stock Symbol for Vaccinex Inc?
The stock symbol for Vaccinex Inc is "VCNX."
What Stock Exchange Does Vaccinex Inc Trade On?
Vaccinex Inc is listed and trades on the OTC Markets stock exchange.
Is Vaccinex Inc a Good Stock to Buy?
Determining whether Vaccinex Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VCNX quote. (ISIN: US9186403013)
OTC Markets
Currency in USD
1.000
0.000(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.000
1.000
52 wk Range
0.310
1.500
VCNX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.0001.000
52 wk Range
0.3101.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VCNX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Vaccinex director resigns, no disagreement cited
- Investing.com
Vaccinex to present pepinemab data at ASCO 2025- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Earnings
Latest Release
Apr 15, 2025
EPS / Forecast
-1.05 / --
Revenue / Forecast
213K / --
Compare VCNX to Peers and Sector
Metrics to compare | VCNX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVCNXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −9.3x | −0.4x | |
PEG Ratio | 0.00 | −0.23 | 0.00 | |
Price/Book | 0.0x | 2.2x | 2.6x | |
Price / LTM Sales | 0.0x | 14.3x | 3.0x | |
Upside (Analyst Target) | 0.0% | 98.3% | 54.5% | |
Fair Value Upside | Unlock | −3.4% | 7.2% | Unlock |
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company’s lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer’s disease and has completed phase 2 study for the treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer. The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses. In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Vaccinex (VCNX) Stock Price Today?
The Vaccinex stock price today is 1.000 USD.
What Stock Exchange Does Vaccinex Trade On?
Vaccinex is listed and trades on the OTC Markets.
What Is the Stock Symbol for Vaccinex?
The stock symbol for Vaccinex is "VCNX."
What Is the Vaccinex Market Cap?
As of today, Vaccinex market cap is 2.680M USD.
What Is Vaccinex's Earnings Per Share (TTM)?
The Vaccinex EPS (TTM) is -8.878.
From a Technical Analysis Perspective, Is VCNX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Vaccinex Stock Split?
Vaccinex has split 2 times.
How Many Employees Does Vaccinex Have?
Vaccinex has 25 employees.
What is the current trading status of Vaccinex (VCNX)?
As of Sep 20, 2026, Vaccinex (VCNX) is trading at a price of 1.000 USD, with a previous close of 1.000 USD. The stock has fluctuated within a day range of 1.000 USD to 1.000 USD, while its 52-week range spans from 0.310 USD to 1.500 USD.
What Is the VCNX After Hours Price?
VCNX's last after hours stock price is 1.420 USD, the stock has decreased by 0.010, or 0.710%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.